ABOUT THE RESEARCHER

OVERVIEW

Gregory S. Sawicki, MD, MPH, is a pediatric pulmonologist and health services researcher with particular interest in addressing health outcomes, disease self-management, and adherence for children, adolescents, and young adults with chronic respiratory diseases including cystic fibrosis (CF) and asthma.

Dr. Sawicki’s primary research activities are currently focused on the process and outcomes of transition from pediatric to adult focused health care for adolescents with chronic medical conditions. He is conducting a NIH-funded mixed methods qualitative and survey study of adolescents and young adults with CF with the aim of exploring their current experiences with health care transition and disease self-management. In his recent work, he has helped to develop and validate a survey instrument to assess transition readiness for youth with chronic disease, the Transition Readiness Assessment Questionnaire (TRAQ).  This instrument is currently being used in multiple health care transition studies throughout the country. He also is working on the development of quality measures to evaluate the transition to adult care for youth with chronic conditions.

BACKGROUND

Dr. Sawicki received his MD from Harvard Medical School in 2001. He completed residency in Boston Combined Residency Program in Pediatrics in 2004, followed by fellowship in Pediatric Pulmonology at Boston Children’s Hospital (2004-2007). He also completed the Harvard Pediatric Health Services Research Fellowship in 2007, receiving an MPH in Clinical Effectiveness at the Harvard School of Public Health. Dr. Sawicki is currently the Associate Director of the Cystic Fibrosis Center at Boston Children’s Hospital.

Active Projects

2011-2016 Cystic Fibrosis as a Model for Health Care Transition for Chronically Ill Youth

NHLBI K23 HL105541-01A1
Principal Investigator

The goals of this mentored career development award are to understand the barriers and facilitators of the health care transition process from the perspective of adolescents and young adults with cystic fibrosis. The research will provide important information that can be used in designing health care transition programs for adolescents and young adults with chronic medical conditions.

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Neuromechanics and Energetics of Walking With an Ankle Exoskeleton Using Neuromuscular-Model Based Control: A Parameter Study. Front Bioeng Biotechnol. 2021; 9:615358. View abstract
  2. Correction to: 'Cyclically producing the same average muscle-tendon force with a smaller duty increases metabolic rate'. Proc Biol Sci. 2021 Apr 14; 288(1948):20210012. View abstract
  3. Series elasticity facilitates safe plantar flexor muscle-tendon shock absorption during perturbed human hopping. Proc Biol Sci. 2021 Mar 31; 288(1947):20210201. View abstract
  4. The Effects of Ivacaftor on Bone Density and Microarchitecture in Children and Adults with Cystic Fibrosis. J Clin Endocrinol Metab. 2021 Mar 08; 106(3):e1248-e1261. View abstract
  5. Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial. Am J Respir Crit Care Med. 2021 03 01; 203(5):585-593. View abstract
  6. Favorable Clinician Acceptability of Telehealth as Part of the Cystic Fibrosis Care Model during the COVID-19 Pandemic. Ann Am Thorac Soc. 2021 Feb 26. View abstract
  7. Rapid Implementation of Telehealth Services in a Pediatric Pulmonary Clinic During COVID-19. Pediatrics. 2021 Feb 25. View abstract
  8. An evaluation of healthcare utilization and clinical charges in children and adults with cystic fibrosis. Pediatr Pulmonol. 2021 May; 56(5):928-938. View abstract
  9. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respir Med. 2021 Feb 10. View abstract
  10. Improvement of Pulmonary Function in Cystic Fibrosis Patients following Endoscopic Sinus Surgery. Laryngoscope. 2021 Feb 04. View abstract
  11. Evaluating the Impact of Stopping Chronic Therapies after Modulator Drug Therapy in Cystic Fibrosis: The SIMPLIFY Study Design. Ann Am Thorac Soc. 2021 Jan 19. View abstract
  12. Tribulations and (clinical) trials in cystic fibrosis. J Cyst Fibros. 2021 Mar; 20(2):188-190. View abstract
  13. Transition Readiness Not Associated With Measures of Health in Youth With IBD. Inflamm Bowel Dis. 2021 Jan 01; 27(1):49-57. View abstract
  14. Men's health in the modern era of cystic fibrosis. J Cyst Fibros. 2020 Dec 26. View abstract
  15. Monogenic Diabetes in a Child with Cystic Fibrosis: A Case Report and Review of the Literature. J Endocr Soc. 2021 Jan 01; 5(1):bvaa165. View abstract
  16. Decreased survival in cystic fibrosis patients with a positive screen for depression. J Cyst Fibros. 2021 Jan; 20(1):120-126. View abstract
  17. Survey of patients with cystic fibrosis and caregivers decisions regarding CFTR modulators. Pediatr Pulmonol. 2020 11; 55(11):2983-2989. View abstract
  18. Caregiver Burden Due to Pulmonary Exacerbations in Patients with Cystic Fibrosis. J Pediatr. 2019 12; 215:164-171.e2. View abstract
  19. Male gender and unemployment are associated with lower levels of perceived social support in adults with cystic fibrosis. J Psychosom Res. 2019 12; 127:109858. View abstract
  20. Medical Deferred Action - Living on Borrowed Time. N Engl J Med. 2019 Oct 24; 381(17):1601-1603. View abstract
  21. Predictors of pulmonary exacerbation treatment in cystic fibrosis. J Cyst Fibros. 2020 05; 19(3):407-414. View abstract
  22. A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11?years with cystic fibrosis. J Cyst Fibros. 2019 09; 18(5):708-713. View abstract
  23. Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries. J Cyst Fibros. 2020 01; 19(1):68-79. View abstract
  24. Chronic rhino-sinusitis treatment in children with cystic fibrosis: A cross-sectional survey of pediatric pulmonologists and otolaryngologists. Int J Pediatr Otorhinolaryngol. 2019 Sep; 124:139-142. View abstract
  25. An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5?years (KLIMB). J Cyst Fibros. 2019 11; 18(6):838-843. View abstract
  26. Developing Sexual and Reproductive Health Educational Resources for Young Women with Cystic Fibrosis: A Structured Approach to Stakeholder Engagement. Patient. 2019 04; 12(2):267-276. View abstract
  27. Linkage of the CF foundation patient registry with the pediatric health information system database. Pediatr Pulmonol. 2019 06; 54(6):721-728. View abstract
  28. Interprofessional provider educational needs and preferences regarding the provision of sexual and reproductive health care in cystic fibrosis. J Cyst Fibros. 2019 09; 18(5):671-676. View abstract
  29. Social support is associated with fewer reported symptoms and decreased treatment burden in adults with cystic fibrosis. J Cyst Fibros. 2019 07; 18(4):572-576. View abstract
  30. Cystic Fibrosis And Ivacaftor Use: The Authors Reply. Health Aff (Millwood). 2019 02; 38(2):328. View abstract
  31. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. Lancet Respir Med. 2019 04; 7(4):325-335. View abstract
  32. Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010-2016. Pediatr Pulmonol. 2018 12; 53(12):1611-1618. View abstract
  33. Disparities in Mortality of Hispanic Patients with Cystic Fibrosis in the United States. A National and Regional Cohort Study. Am J Respir Crit Care Med. 2018 10 15; 198(8):1055-1063. View abstract
  34. Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities. J Clin Transl Sci. 2018 Oct; 2(5):334-342. View abstract
  35. Rate and predictors of prescription of lumacaftor - Ivacaftor in the 18?months following approval in the United States. J Cyst Fibros. 2018 11; 17(6):742-746. View abstract
  36. Sexual and Reproductive Health of Young Women With Cystic Fibrosis: A Concept Mapping Study. Acad Pediatr. 2019 04; 19(3):307-314. View abstract
  37. The burden of cystic fibrosis in the Medicaid population. Clinicoecon Outcomes Res. 2018; 10:423-431. View abstract
  38. Overcoming psychosocial challenges in cystic fibrosis: Promoting resilience. Pediatr Pulmonol. 2018 11; 53(S3):S86-S92. View abstract
  39. Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Thorax. 2018 08; 73(8):731-740. View abstract
  40. Precision Medicine In Action: The Impact Of Ivacaftor On Cystic Fibrosis-Related Hospitalizations. Health Aff (Millwood). 2018 05; 37(5):773-779. View abstract
  41. Perspectives of adolescent girls with cystic fibrosis and parents on disease-specific sexual and reproductive health education. Pediatr Pulmonol. 2018 08; 53(8):1027-1034. View abstract
  42. Association of High-Dose Ibuprofen Use, Lung Function Decline, and Long-Term Survival in Children with Cystic Fibrosis. Ann Am Thorac Soc. 2018 04; 15(4):485-493. View abstract
  43. Cystic fibrosis patient registries: A valuable source for clinical research. J Cyst Fibros. 2018 07; 17(4):433-440. View abstract
  44. Outcome evaluation of a pharmacy-based therapy management program for patients with cystic fibrosis. Pediatr Pulmonol. 2018 06; 53(6):720-727. View abstract
  45. Risk Factors for Gaps in Care during Transfer from Pediatric to Adult Cystic Fibrosis Programs in the United States. Ann Am Thorac Soc. 2018 02; 15(2):234-240. View abstract
  46. Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis. J Cyst Fibros. 2018 05; 17(3):e25-e31. View abstract
  47. Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation. J Cyst Fibros. 2018 07; 17(4):503-510. View abstract
  48. Sexual and reproductive health care utilization and preferences reported by young women with cystic fibrosis. J Cyst Fibros. 2018 01; 17(1):64-70. View abstract
  49. Mental Health Screening of Medically-Admitted Patients With Cystic Fibrosis. Psychosomatics. 2018 Mar - Apr; 59(2):158-168. View abstract
  50. Incident Stenotrophomonas maltophilia infection and lung function decline in cystic fibrosis. Pediatr Pulmonol. 2017 10; 52(10):1276-1282. View abstract
  51. Early Lung Function Decline in Cystic Fibrosis. Can Registry Data Explain Divergent Phenotypes? Am J Respir Crit Care Med. 2017 08 15; 196(4):407-409. View abstract
  52. Pediatric lung transplantation and end of life care in cystic fibrosis: Barriers and successful strategies. Pediatr Pulmonol. 2017 Nov; 52(S48):S61-S68. View abstract
  53. Sexual and reproductive health behaviors and experiences reported by young women with cystic fibrosis. J Cyst Fibros. 2018 01; 17(1):57-63. View abstract
  54. Preparation for Transition to Adult Care Among Medicaid-Insured Adolescents. Pediatrics. 2017 Jul; 140(1). View abstract
  55. Patients with Cystic Fibrosis and a G551D or Homozygous F508del Mutation: Similar Lung Function Decline. Am J Respir Crit Care Med. 2017 06 15; 195(12):1673-1676. View abstract
  56. Impact of an Individual Mandate and Other Health Reforms on Dependent Coverage for Adolescents and Young Adults. Health Serv Res. 2018 06; 53(3):1581-1599. View abstract
  57. Utilization of a patient-centered asthma passport tool in a subspecialty clinic. J Asthma. 2018 02; 55(2):180-187. View abstract
  58. Microbiology of the Upper and Lower Airways in Pediatric Cystic Fibrosis Patients. Otolaryngol Head Neck Surg. 2017 08; 157(2):302-308. View abstract
  59. Correlation of Transient Elastography With Severity of Cystic Fibrosis-related Liver Disease. J Pediatr Gastroenterol Nutr. 2017 04; 64(4):505-511. View abstract
  60. The CF-CARES primary palliative care model: A CF-specific structured assessment of symptoms, distress, and coping. J Cyst Fibros. 2018 01; 17(1):71-77. View abstract
  61. Adherence and Recursive Perception Among Young Adults with Cystic Fibrosis. Anthropol Med. 2017 Apr; 24(1):65-80. View abstract
  62. Counterpoint: Too little care or too little collaboration: Approaches to treatment refusal in CF. J Cyst Fibros. 2017 03; 16(2):304-305. View abstract
  63. Provider Attitudes and Practices toward Sexual and Reproductive Health Care for Young Women with Cystic Fibrosis. J Pediatr Adolesc Gynecol. 2017 Oct; 30(5):546-552. View abstract
  64. Obesity and Airway Dysanapsis in Children with and without Asthma. Am J Respir Crit Care Med. 2017 Feb 01; 195(3):314-323. View abstract
  65. Reply: Combining Clinical Trial and Patient Registry Data in Cystic Fibrosis: Who Should Be Compared? Am J Respir Crit Care Med. 2017 02 01; 195(3):405-406. View abstract
  66. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med. 2017 02; 5(2):107-118. View abstract
  67. Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder. Patient Prefer Adherence. 2016; 10:2163-2169. View abstract
  68. Strategies to optimize treatment adherence in adolescent patients with cystic fibrosis. Adolesc Health Med Ther. 2016; 7:117-124. View abstract
  69. Transition and transfer of childhood cancer survivors to adult care: A national survey of pediatric oncologists. Pediatr Blood Cancer. 2017 02; 64(2):346-352. View abstract
  70. Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis. J Med Econ. 2016 Sep; 19(9):845-51. View abstract
  71. Young adults with cystic fibrosis have altered trabecular microstructure by ITS-based morphological analysis. Osteoporos Int. 2016 08; 27(8):2497-505. View abstract
  72. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med. 2016 Feb; 4(2):107-15. View abstract
  73. Risk Factors for Hearing Loss in Patients with Cystic Fibrosis. J Am Acad Audiol. 2016 01; 27(1):6-12. View abstract
  74. A Simple Model to Estimate Plantarflexor Muscle-Tendon Mechanics and Energetics During Walking With Elastic Ankle Exoskeletons. IEEE Trans Biomed Eng. 2016 05; 63(5):914-923. View abstract
  75. Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Am J Respir Crit Care Med. 2015 Oct 01; 192(7):836-42. View abstract
  76. Tackling the increasing complexity of CF care. Pediatr Pulmonol. 2015 Oct; 50 Suppl 40:S74-9. View abstract
  77. Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years. J Pediatr. 2015 Nov; 167(5):1081-8.e1. View abstract
  78. Development and Validation of the Adolescent Assessment of Preparation for Transition: A Novel Patient Experience Measure. J Adolesc Health. 2015 Sep; 57(3):282-7. View abstract
  79. Rate of Uptake of Ivacaftor Use after U.S. Food and Drug Administration Approval among Patients Enrolled in the U.S. Cystic Fibrosis Foundation Patient Registry. Ann Am Thorac Soc. 2015 Aug; 12(8):1146-52. View abstract
  80. A randomized controlled trial of vitamin D replacement strategies in pediatric CF patients. J Cyst Fibros. 2016 Mar; 15(2):234-41. View abstract
  81. Self-Management and Transition Readiness Assessment: Concurrent, Predictive and Discriminant Validation of the STARx Questionnaire. J Pediatr Nurs. 2015 Sep-Oct; 30(5):668-76. View abstract
  82. Predictors of timing of transfer from pediatric- to adult-focused primary care. JAMA Pediatr. 2015 Jun; 169(6):e150951. View abstract
  83. Similar performance of Brasfield and Wisconsin scoring systems in young children with cystic fibrosis. Pediatr Radiol. 2015 Oct; 45(11):1624-8. View abstract
  84. Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients. J Cyst Fibros. 2015 Nov; 14(6):777-83. View abstract
  85. Development and evaluation of a palliative care curriculum for cystic fibrosis healthcare providers. J Cyst Fibros. 2016 Jan; 15(1):90-5. View abstract
  86. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site. Pediatr Pulmonol. 2015 May; 50(5):431-40. View abstract
  87. Ready, set, stop: mismatch between self-care beliefs, transition readiness skills, and transition planning among adolescents, young adults, and parents. Clin Pediatr (Phila). 2014 Oct; 53(11):1062-8. View abstract
  88. The Transition Readiness Assessment Questionnaire (TRAQ): its factor structure, reliability, and validity. Acad Pediatr. 2014 Jul-Aug; 14(4):415-22. View abstract
  89. Compromised bone microarchitecture and estimated bone strength in young adults with cystic fibrosis. J Clin Endocrinol Metab. 2014 Sep; 99(9):3399-407. View abstract
  90. Inter-hospital variation in the frequency of sinus surgery in children with cystic fibrosis. Pediatr Pulmonol. 2015 Mar; 50(3):231-235. View abstract
  91. Motivating adherence among adolescents with cystic fibrosis: youth and parent perspectives. Pediatr Pulmonol. 2015 Feb; 50(2):127-36. View abstract
  92. Transition care: future directions in education, health policy, and outcomes research. Acad Pediatr. 2014 Mar-Apr; 14(2):120-7. View abstract
  93. Vitamin D status in children with cystic fibrosis. Associations with inflammation and bacterial colonization. Ann Am Thorac Soc. 2014 Feb; 11(2):205-10. View abstract
  94. Transition and transfer of adolescents and young adults with pediatric onset chronic disease: the patient and parent perspective. J Pediatr Rehabil Med. 2014; 7(1):43-51. View abstract
  95. Brasfield and Wisconsin scoring systems have equal value as outcome assessment tools of cystic fibrosis lung disease. Pediatr Radiol. 2014 May; 44(5):529-34. View abstract
  96. Longitudinal trends in health-related quality of life in adults with cystic fibrosis. Chest. 2013 Sep; 144(3):981-989. View abstract
  97. Claim-based analyses of inhaled corticosteroid refill rates for asthma: who's kidding whom? Ann Am Thorac Soc. 2013 Apr; 10(2):149-50. View abstract
  98. Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes. J Cyst Fibros. 2013 Sep; 12(5):461-7. View abstract
  99. A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care. Pediatr Pulmonol. 2013 Oct; 48(10):954-61. View abstract
  100. Referral patterns and perceived barriers to adult congenital heart disease care: results of a survey of U.S. pediatric cardiologists. J Am Coll Cardiol. 2012 Dec 11; 60(23):2411-8. View abstract
  101. Managing treatment complexity in cystic fibrosis: challenges and opportunities. Pediatr Pulmonol. 2012 Jun; 47(6):523-33. View abstract
  102. Erratum to: Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national, US sample. Qual Life Res. 2012 Sep; 21(7):1279-90. View abstract
  103. The impact of reflux burden on Pseudomonas positivity in children with cystic fibrosis. Pediatr Pulmonol. 2012 Jun; 47(6):582-7. View abstract
  104. Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample. Qual Life Res. 2012 Sep; 21(7):1267-78. View abstract
  105. Physician practices for communicating with patients with cystic fibrosis about the use of noninvasive and invasive mechanical ventilation. Chest. 2012 Apr; 141(4):1010-1017. View abstract
  106. Assessment of current strategies for weaning premature infants from supplemental oxygen in the outpatient setting. Adv Neonatal Care. 2011 Oct; 11(5):349-56. View abstract
  107. Receipt of health care transition counseling in the national survey of adult transition and health. Pediatrics. 2011 Sep; 128(3):e521-9. View abstract
  108. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol. 2012 Jan; 47(1):44-52. View abstract
  109. Tree nut allergy, egg allergy, and asthma in children. Clin Pediatr (Phila). 2011 Feb; 50(2):133-9. View abstract
  110. Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis. Pediatr Pulmonol. 2011 Jan; 46(1):36-44. View abstract
  111. Employment experiences among adolescents and young adults with cystic fibrosis. Disabil Rehabil. 2011; 33(11):922-6. View abstract
  112. Associations between illness perceptions and health-related quality of life in adults with cystic fibrosis. J Psychosom Res. 2011 Feb; 70(2):161-7. View abstract
  113. Uncontrolled asthma in a commercially insured population from 2002 to 2007: trends, predictors, and costs. J Asthma. 2010 Jun; 47(5):574-80. View abstract
  114. Cystic fibrosis and transition to adult medical care. Pediatrics. 2010 Mar; 125(3):566-73. View abstract
  115. Patterns of inhaled corticosteroid use and asthma control in the Childhood Asthma Management Program Continuation Study. Ann Allergy Asthma Immunol. 2010 Jan; 104(1):30-5. View abstract
  116. Asthma care quality for children with minority-serving providers. Arch Pediatr Adolesc Med. 2010 Jan; 164(1):38-45. View abstract
  117. Measuring the transition readiness of youth with special healthcare needs: validation of the TRAQ--Transition Readiness Assessment Questionnaire. J Pediatr Psychol. 2011 Mar; 36(2):160-71. View abstract
  118. Travel patterns to school among children with asthma. Clin Pediatr (Phila). 2009 Jul; 48(6):632-40. View abstract
  119. The impact of MRSA on lung function in patients with cystic fibrosis. Am J Respir Crit Care Med. 2009 Apr 15; 179(8):734-5; author reply 735. View abstract
  120. The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. Pediatr Pulmonol. 2008 Nov; 43(11):1117-1123. View abstract
  121. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros. 2009 Mar; 8(2):91-6. View abstract
  122. Advance care planning in adults with cystic fibrosis. J Palliat Med. 2008 Oct; 11(8):1135-41. View abstract
  123. Necrotising pneumonia is an increasingly detected complication of pneumonia in children. Eur Respir J. 2008 Jun; 31(6):1285-91. View abstract
  124. Self-reported physical and psychological symptom burden in adults with cystic fibrosis. J Pain Symptom Manage. 2008 Apr; 35(4):372-80. View abstract
  125. Periodic use of inhaled steroids in children with mild persistent asthma: what are pediatricians recommending? Clin Pediatr (Phila). 2008 Jun; 47(5):446-51. View abstract
  126. Bronchoscopy findings in children and young adults with tracheostomy due to congenital anomalies and neurological impairment. J Pediatr Rehabil Med. 2008; 1(2):137-43. View abstract
  127. Mucoepidermoid carcinoma of bronchus in a pediatric patient: (18)F-FDG PET findings. Pediatr Radiol. 2007 Dec; 37(12):1278-82. View abstract
  128. Self-reported involvement of family members in the care of adults with CF. J Cyst Fibros. 2008 Mar; 7(2):95-101. View abstract
  129. Adults with cystic fibrosis report important and unmet needs for disease information. J Cyst Fibros. 2007 Nov 30; 6(6):411-6. View abstract
  130. Phenotypic and cytokine analysis of human peripheral blood gamma delta T cells expressing NK cell receptors. J Immunol. 1997 Oct 15; 159(8):3723-30. View abstract